This project presents one application direction of the IARIP research architecture. The presented model is currently in the research and pilot validation phase. The timelines below outline the expected validation and development steps of the IARIP research architecture across different application domains. Following research validation, IARIP aims to initiate real-world projects together with industry and market partners based on the successfully validated models.

Developing high-value bio-based health products and export-ready nutraceuticals at national scale

Program Objective and Strategic Role

The National Bioactive and Nutraceutical Innovation Program aims to establish a national development and industrialization framework that leverages domestic biological, botanical, and agricultural resources to support the research, development, and market deployment of high value-added bioactive and nutraceutical products.

The program is not pharmaceutical drug development, but focuses on:

• – dietary supplements and functional bioactive products,
• – prevention- and quality-of-life–oriented health solutions,
• – strengthening collaboration between research institutions, industry, and the public sector.

Core Program Logic

The program integrates three domains into a unified system:

1. Natural and Agricultural Foundations

• – domestic plant-based, microbial, and bio-derived resources,
• – sustainable cultivation and processing models,
• – traceable and transparent raw-material supply chains.

2. Scientific and Technological Development

• – bioactive compound research,
• – AI- and bioinformatics-supported formulation design,
• – quality assurance and validation methodologies.

3. Industrialization and Market Deployment

• – pilot manufacturing and scalable production,
• – regulation-compliant product positioning,
• – support for domestic and international market entry.

Key Development Pillars

1. National Bioactive Research and Formulation Platform

• – centralized bioactive compound databases,
• – analysis of synergistic interactions and mechanisms of action,
• – reproducible and standardized development workflows.

2. Nutraceutical Pilot and Scaling Program

• – development of pilot product lines,
• – involvement of small and medium-sized manufacturers,
• – quality-assured production models.

3. Regulatory and Market Support Framework

• – EU-compliant regulatory alignment,
• – support for documentation and approval processes,
• – export and brand development initiatives.

Program Phases (2–6 Years)

Phase 1 – Foundation and Pilot Phase (Years 1–2)

• – mapping of national bioactive resources,
• – launch of pilot nutraceutical development projects,
• – formation of research–industry consortia.

Phase 2 – Industrialization and Expansion (Years 3–4)

• – expansion of manufacturing capacities,
• – diversification of product portfolios,
• – entry into regional and EU markets.

Phase 3 – Consolidation and International Positioning (Years 5–6)

• – development of export-ready brands,
• – establishment of long-term industrial partnerships,
• – strengthening international presence in the health industry.

Institutional and Industry Stakeholders

• – agricultural and food-industry actors,
• – nutraceutical and functional food manufacturers,
• – universities and research institutes,
• – innovation and development agencies,
• – export and foreign-trade organizations.

Expected Economic and Societal Impact

• – creation of a high value-added national health-industry segment,
• – job creation and SME development,
• – growth in export revenues,
• – increased consumer health awareness,
• – sustainable bio-based economic models.

Alignment with the AVA Development Framework

Within this program, AVA functions as a development-support intelligence layer, enabling:

• – dentification of bioactive patterns and synergistic combinations,
• – support for formulation and portfolio decisions,
• – prioritization of market and development pathways.

The National Bioactive and Nutraceutical Innovation Program thus represents a commercially tangible yet scientifically grounded pillar of the national Bio–Nano and health-technology strategy.